我們已在上線！進一步了解

Mesa Laboratories

MLAB

市值 US$6.85億

122.48 USD

-5.26

4.12%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

122.48

0.00

0%

1天

-4.12%

5天

-3.83%

1個月

-2.24%

3個月

23.17%

6個月

24.03%

今年迄今

54.2%

1年

65.18%

5年

-59.44%

10年

4.35%

關於： Mesa Laboratories Inc manufactures life sciences tools and critical quality control solutions. It operates in four divisions: i) Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. ii) Clinical Genomics division develops, manufactures, and sells sensitive, low-cost, high-throughput genetic analysis tools and related consumables. iii) The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. iv) The Calibration Solutions division develops, manufactures, sells, and services quality control products.

員工： 717

科技科學與技術儀器

新聞

正面

中性

負面

市場情緒 3個月

正面 25%

中性 75%

負面 0%

Mesa Laboratories Announces Restructuring and Savings Plan to Reduce Annualized Costs by Approximately $9.3 Million and Reinvest Approximately $4.3 Million in Profitable Growth

LAKEWOOD, Colo., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ: MLAB) (“Mesa,” “we,” “us” or “our”), a global leader in the design and manufacture of critical quality control solutions and life sciences tools, today announced a savings plan (the “Savings Plan”) expected to reduce annualized operating costs by approximately $9.3 million.

Mesa Laboratories Announces Restructuring and Savings Plan to Reduce Annualized Costs by Approximately $9.3 Million and Reinvest Approximately $4.3 Million in Profitable Growth

Mesa Laboratories, Inc. (MLAB) Q1 2027 Earnings Call Transcript

Mesa Laboratories, Inc. (MLAB) Q1 2027 Earnings Call Transcript

Mesa Laboratories, Inc. (MLAB) Q1 2027 Earnings Call Transcript

Mesa Laboratories Q1 Earnings Call Highlights

Mesa Laboratories NASDAQ: MLAB reported first-quarter fiscal 2027 revenue growth of 1%, improved operating margins and continued debt reduction, while newly appointed President and CEO Siddhartha Kadia outlined plans to address fulfillment issues in its Sterilization and Disinfection Control business and accelerate product development in Biopharmaceutical Development.

Mesa Laboratories Q1 Earnings Call Highlights

Mesa Labs Announces First Quarter Financial Results Release Date and Inaugural Earnings Conference Call

LAKEWOOD, Colo., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced it will release financial results for its first fiscal quarter (“1Q27”) ended June 30, 2026 following market close on Monday, August 10, 2026. The Company will also hold its first earnings conference call the same day at 4:30 p.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with analysts.

Mesa Labs Announces First Quarter Financial Results Release Date and Inaugural Earnings Conference Call

MESA LABS DECLARES QUARTERLY DIVIDEND

Lakewood, Colo., July 06, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 15, 2026, to shareholders of record at the close of business on August 31, 2026.

MESA LABS DECLARES QUARTERLY DIVIDEND

The Motley Fool

Why Mesa Laboratories Stock Is Getting Hit With a Huge Sell-Off Today

Mesa Laboratories fell after reporting its Q4 fiscal 2026 results. Sales and earnings came in below Wall Street's expected earnings, but the business did report strong growth for adjusted operating income.

Why Mesa Laboratories Stock Is Getting Hit With a Huge Sell-Off Today

Mesa Labs Announces Fourth Quarter and Fiscal Year 2026 Results

LAKEWOOD, Colo., May 27, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of life science tools and critical quality control solutions, today announced results for its fourth fiscal quarter (“4Q26”) and fiscal year (“FY26”) ended March 31, 2026 (amounts in thousands).

Mesa Labs Announces Fourth Quarter and Fiscal Year 2026 Results

Mesa Laboratories, Inc. to Announce Fourth Quarter and Full Fiscal Year Results on May 27, 2026

LAKEWOOD, Colo., May 05, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) will issue a press release with financial results for the fourth quarter and the fiscal year ended March 31, 2026 at approximately 6:00 A.M. Eastern Time (ET) on Wednesday, May 27, 2026.

Mesa Laboratories, Inc. to Announce Fourth Quarter and Full Fiscal Year Results on May 27, 2026

Royce Small-Cap Fund FY 2025: What Worked

Five of the Fund's 10 equity sectors made a positive impact on calendar year performance, led by Industrials, Financials, and Information Technology. Alamos Gold's positive earnings outlook, a renewed stock buyback program, and rising gold prices all helped its stock to climb throughout 2025. Management reported a 48% increase in total revenue for 1Q25 compared to 1Q24, driven by OCS liver and heart transplants.

Royce Small-Cap Fund FY 2025: What Worked

Mesa Laboratories, Inc. (MLAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Mesa Laboratories, Inc. (MLAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Mesa Laboratories, Inc. (MLAB) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

查看新聞排名

價格圖表採用Lightweight Charts™實作